期刊文献+

外消旋2-羟基-3-甲氧基-3,3-二苯基丙酸的手性拆分研究 被引量:1

Chiral Resolution of 2-hydroxy-3-methoxy-3,3-diphenyl-propionic Acid
暂未订购
导出
摘要 研究并优化了标题化合物的手性拆分工艺,获得其单一的S型异构体。以(S)-4-硝基-1-苯乙胺盐酸盐为手性拆分剂,与标题化合物生成非对映异构体,利用两者溶解性差异来进行手性拆分,得到中间体(S)-2-羟基-3-甲氧基-3,3-二苯基丙酸(S)-4-硝基-1-苯乙胺盐,经酸性游离后得到产物(S)-2-羟基-3-甲氧基-3,3-二苯基丙酸。对溶剂量、拆分剂的量、缚酸剂的量以及重结晶条件进行了考察,同时对手性拆分剂进行了回收。结果表明,以100 g标题化合物为起始原料,20倍体积的无水乙醇为溶剂,1.5倍物质的量的三乙胺为缚酸剂并使用0.75倍物质的量的拆分剂进行拆分时,得到了较好的产率(40.6%)和光学纯度(82.8%e.e.),经进一步重结晶达到质量要求(e.e.>99.00%)。该工艺具有操作简便、产品成本低且质量较高的优点,适用于工业化生产。 Research and optimize the chiral resolution of racemic 2-hydroxy-3-methoxy-3,3-diphenyl-propionic acid to obtain its single S-isomer. As a chiral resolving agent,( S)-1-( 4-Nitro-phenyl)-ethylamine hydrochloride salifys with 2-hydroxy-3-methoxy-3,3-diphenyl-propionic acid and generates a couple of diastereoisomers,which can be separated by their different solubility in solution. Acidize the diastereoisomer intermediate to obtain the product( S)-2-hydroxy-3-methoxy-3,3-diphenyl-propionic acid. The amount of solvent,resolving agent,acidscavenger,recrystallization condition and the chiral resolving agent’s reclamation have been investigated. With 100 g racemic 2-hydroxy-3-methoxy-3,3-diphenyl-propionic acid as start material,in the condition of 20 equivalent of ethanol as solvent,1. 5 equivalent of triethylamine as acidscavenger and 0. 75 equivalent of solving agent,the resolution obtains the best yield( 40. 6%) and optical purity( 82. 8% e. e.),which can reachthe quality requirement( e. e.〉 99. 00%) after further recrystallization. With the advantages of simple in process,low-cost of raw materials and high-quality of product,the chiral resolution is suitable for industrial production.
出处 《化学试剂》 CAS 北大核心 2015年第7期639-642,共4页 Chemical Reagents
关键词 2-羟基-3-甲氧基-3 3-二苯基丙酸 (S)-4-硝基-1-苯乙胺盐酸盐 手性拆分 2-hydroxy-3-methoxy-3,3-diphenyl-propionic acid (S)-1-(4-nitro-phenyl)-ethylamine hydrochloride salifys chiral resolution
  • 相关文献

参考文献8

  • 1CASSERLY B,KLINGER J R. Ambrisentan for the treat- ment of pulmonary arterial hypertension [J].Drug Des. Dev. Ther. ,2008,2:265-280.
  • 2NEWMAN J H, KAR S, KIRKPATRICK P. Fresh from the pipeline: ambrisentan [ J ]. Nat. Rev. Drug Discov. , 2007.9 ( 6 ) : 697 -698.
  • 3谭初兵,沈丹.达卢生坦[J].现代药物与临床,2009,24(1):57-59. 被引量:1
  • 4CadiIa Healthcare Limited. Improved process for the prep- aration of ambrisentan and novel intermediates thereof: W O, 2 011 004 402 [ P ]. 2009-07 - 10.
  • 5周付刚,谷建敏,苏信杰,邢松松,杜玉民.安贝生坦的合成[J].中国医药工业杂志,2010,41(1):1-3. 被引量:11
  • 6JANSEN R, KNOPP M, AMBERG W, et al. Structural similarity and its surprises: endothelin receptor antago- nists [ J ]. Org. Pro. Res. Dev. , 2001 ,5 ( 1 ) : 16-22.
  • 7刘爱霞,陈一芬,禹艳坤,王超,冀亚飞.安贝生坦合成的改进[J].化学世界,2011,52(2):100-102. 被引量:8
  • 8RIECHERS H, KLINGE D, AMBERG W, et al. a- Hydrdroxylic acid derivatives, their production and use: DE, 19 533 023 [ P]. 1996-04-18.

二级参考文献18

  • 1郭峰,陈益奇,吉民,华维一.选择性内皮素受体阻滞剂darusentan的合成[J].中国新药杂志,2005,14(2):172-173. 被引量:2
  • 2郭文.肺动脉高压治疗的潜力药物即将崛起[J].上海医药,2007,28(4):160-161. 被引量:2
  • 3Hrometz SL, Shields KM. Role of ambrisentan in the management of pulmonary hypertension [J]. Ann Pharmacother, 2008, 42 (11) : 1653-1659.
  • 4Cheng JW. Ambrisentan for the management of pulmonary arterial hypertension [J]. Clin Ther, 2008, 30 (5) : 825-833.
  • 5Riechers H, Albrecht HE Amberg W, et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists [J]. J Med Chem, 1996, 39 (11) : 2123-2128.
  • 6Riechers H, Klinge D, Amberg W, et al. New carboxylic acid derivatives, their preparation and their use: EP, 0785926 [P]. 2001-08-22.
  • 7Jansen R, Knopp M, Amberg W, et al. Structural similarity and its surprises: endothelin receptor antagonists--Process research and development report [J]. Org Proc Res Dev, 2001, 5(1): 16-22.
  • 8mberg W, Hergenrder S, Hillen H, et al. Discovery and synthesis of (S) -3- [2- (3,4-dimethoxyphenyl) ethoxy] -2- (4,6-dimethylpyrimidin-2-yloxy)-3,3- diphenylpropionic acid (LU302872), a novel orally active mixed ET/ET receptor antagonist [J]. J Med Chem, 1999, 42 (16) : 3026-3032.
  • 9Bessard Y, Crettaz R. Rate acceleration of nucleophilic substitution of 2-chloro-4,6-dimethoxypyrimidine by sulfinate catalysis [J]. Tetrahedron, 2000, 56 (27) : 4739-4745.
  • 10Riechers H,Albrecht H P,Amberg W,etal.J Med Chem[J],1996,39(11).2123-2128.

共引文献12

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部